Author:
Rizzini Elisa Lodi,Dionisi Valeria,Ghedini Pietro,Morganti Alessio Giuseppe,Fanti Stefano,Monari Fabio
Abstract
AbstractBone is the most common site of metastasis in metastatic castration-resistant prostate cancer (mCRPC), which is associated with pain and skeletal events. Radium-223 dichloride (Xofigo) is an alpha-emitting radioactive isotope that can specifically target bone lesions. Herein, we report the results of a retrospective analysis that documents our experience in the use of radium-223. Data from 63 patients (pts) with mCRPC who underwent radium-223 treatment from December 2015 to September 2017 were collected. Radium-223 (55 kBq/kg) was administered every 4 weeks for up to 6 cycles. The primary endpoint was OS. Radium-223 was administered as first line therapy in 11 pts, as second line in 19 pts, as third line in 16 pts and in successive lines in 17 pts; 42 pts out of 63 (67%) completed all six cycles. Within one month after the end of 6 cycles of radium-223, 15 pts out of 42 (35.7%) had achieved PR, 11 pts out of 42 (26.2%) had SD and 14 pts out of 42 (33.3%) had PD. Levels of pain decreased with progressive cycles of radium-223. After a minimum follow-up of 2 months and a maximum of 43 months, median OS was 15 months and median PFS was 8 months. The most frequent radium-223 related toxicity was low grade haematologic toxicity, predominantly G1-G2, that occurred halfway through treatment in about 75% of pts. The favourable results reported herein confirm that radium-223 can be considered well tolerated and effective in mCRPC, and is associated with significant decreases in pain.
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Leslie, S. W., Soon-Sutton, T. L., Sajjad, H. & Siref, L. E. Prostate Cancer. [Updated 2019 Oct 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan. Available from, https://www.ncbi.nlm.nih.gov/books/NBK470550/.
2. Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103, 356–387, https://doi.org/10.1016/j.ejca.2018.07.005 (2018).
3. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J Clin 66, 7–30, https://doi.org/10.3322/caac.21332 (2016).
4. Bubendorf, L. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31, 578–583 (2000).
5. Logothetis, C., Morris, M. J., Den, R. & Coleman, R. E. Current perspectives on bone metastases in castrate-resistant prostate cancer. Cancer Metastasis Rev 37, 189–196, https://doi.org/10.1007/s10555-017-9719-4 (2018).
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献